GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma

Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Johnson, 2013, Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study, J Clin Oncol, 31, 3517, 10.1200/JCO.2012.48.4410 Cainap, 2015, Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial, J Clin Oncol, 33, 172, 10.1200/JCO.2013.54.3298 Cheng, 2013, Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial, J Clin Oncol, 31, 4067, 10.1200/JCO.2012.45.8372 Cabanillas, 2016, Lenvatinib: Role in thyroid cancer and other solid tumors, Cancer Treat Rev, 42, 47, 10.1016/j.ctrv.2015.11.003 Tohyama, 2014, Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models, J Thyroid Res, 2014, 1, 10.1155/2014/638747 Okamoto, 2013, Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models, Cancer Lett, 340, 97, 10.1016/j.canlet.2013.07.007 Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1 Redza-Dutordoir, 2016, Activation of apoptosis signalling pathways by reactive oxygen species, Biochim Biophys Acta, 1863, 2977, 10.1016/j.bbamcr.2016.09.012 Cui, 2018, Modulating ROS to overcome multidrug resistance in cancer, Drug Resist Updat, 41, 1, 10.1016/j.drup.2018.11.001 Pajic, 2018, miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense, Cancer Res, 78, 501, 10.1158/0008-5472.CAN-16-3105 Xie, 2018, CDK16 Phosphorylates and Degrades p53 to Promote Radioresistance and Predicts Prognosis in Lung Cancer, Theranostics, 8, 650, 10.7150/thno.21963 Coriat, 2012, Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo, Mol Cancer Ther, 11, 2284, 10.1158/1535-7163.MCT-12-0093 Shao, 2016, Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways, Cancer Med, 5, 3166, 10.1002/cam4.881 Houessinon, 2016, Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib, Mol Cancer, 15, 10.1186/s12943-016-0526-2 Bocci, 2018, Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo, Oncol Rep, 39, 2225 Brigelius-Flohé, 2013, Glutathione peroxidases, Biochim Biophys Acta, 1830, 3289, 10.1016/j.bbagen.2012.11.020 Yang, 2014, Regulation of ferroptotic cancer cell death by GPX4, Cell, 156, 317, 10.1016/j.cell.2013.12.010 Huang, 2016, 1,25-Dihydroxyvitamin D3 alleviates salivary adenoid cystic carcinoma progression by suppressing GPX1 expression through the NF-κB pathway, Int J Oncol, 48, 1271, 10.3892/ijo.2016.3341 Huang, 2017, YAP suppresses lung squamous cell carcinoma progression via deregulation of the DNp63-GPX2 axis and ROS accumulation, Cancer Res, 77, 5769, 10.1158/0008-5472.CAN-17-0449 Emmink, 2014, GPx2 suppression of H2O2 stress links the formation of differentiated tumor mass to metastatic capacity in colorectal cancer, Cancer Res, 74, 6717, 10.1158/0008-5472.CAN-14-1645 Suzuki, 2013, Expression of glutathione peroxidase 2 is associated with not only early hepatocarcinogenesis but also late stage metastasis, Toxicology, 311, 115, 10.1016/j.tox.2013.07.005 Sasaki, 2020, Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines, Int J Mol Sci, 21, 3349, 10.3390/ijms21093349 Xu, 2018, Ebselen suppresses inflammation induced by Helicobacter pylori lipopolysaccharide via the p38 mitogen-activated protein kinase signaling pathway, Mol Med Rep, 17, 6847 Matsuki, 2018, Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models, Cancer Med, 7, 2641, 10.1002/cam4.1517 Yi, 2021, Lenvatinib Targets FGFR4 to Enhance Antitumor Immune Response of Anti-PD-1 in Hepatocellular Carcinoma, Hepatology, 10.1002/hep.31921 Tan, 2018, TNF-alpha is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma, EBioMedicine Banning, 2007, Activation of the glutathione peroxidase 2 (GPx2) promoter by beta-catenin, Biol Chem, 388, 1027, 10.1515/BC.2007.137 Kudo, 2018, Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma, Liver Cancer, 7, 1, 10.1159/000487148 Teng, 2017, FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling, Cancer Res, 77, 6215, 10.1158/0008-5472.CAN-17-2039 Wang, 2017, FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib, J Exp Clin Cancer Res, 36, 8, 10.1186/1756-9966-32-8 Miura, 2012, Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma, BMC Cancer, 12, 10.1186/1471-2407-12-56 Tamai, 2017, Dose finding of Lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses, J Clin Pharmacol, 57, 1138, 10.1002/jcph.917 Lee, 2020, A real-world comparative analysis of lenvatinib and Sorafenib as a salvage therapy for transarterial treatments in unresectable HCC, J Clin Med, 9, 4121, 10.3390/jcm9124121 Naiki, 2014, GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer, Carcinogenesis, 35, 1962, 10.1093/carcin/bgu048 Lei, 2016, Clinicopathological and prognostic significance of GPX2 protein expression in esophageal squamous cell carcinoma, BMC Cancer, 16, 10.1186/s12885-016-2462-3 Rebouissou, 2016, Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression, Hepatology, 64, 2047, 10.1002/hep.28638